Supplementary Tables – Prognostic implication of serum AFP in patients with hepatocellular carcinoma treated with regorafenib

Supplementary Table S1. Baseline patient characteristics according to nationality

Supplementary Table S2. Baseline patient characteristics according to AFP response

Supplementary Table S3. Univariate and multivariate analysis for PFS including baseline AFP 

Supplementary Table S4. Univariate and multivariate analysis for PFS including AFP response

Supplementary Table S5. Best overall tumor response by baseline AFP and AFP response

补充表 S1：根据国籍划分的患者基线特征

补充表 S2：根据甲胎蛋白（AFP）反应划分的患者基线特征

补充表 S3：包括基线 AFP 的无进展生存期（PFS）的单因素和多因素分析

补充表 S4：包括 AFP 反应的无进展生存期（PFS）的单因素和多因素分析

补充表 S5：基于基线 AFP 和 AFP 反应的最佳总体肿瘤反应